Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wiemer

Showing results (111-120 of 130) with videos related to

Pageof 13
Sort By:
Cancer Biology & Therapy|November 19, 2005
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genesHerman Burger, Michael A den Bakker, Johan M Kros, et al.
Oncogene|October 10, 2012
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cellsM T M van Jaarsveld, J Helleman, A W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2012
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patientsKarel Eechoute, Martin N Fransson, An K Reyners, et al.
Critical Care Medicine|March 4, 2017
Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) StudyPhilipp Schuetz, Robert Birkhahn, Robert Sherwin, et al.
Nature Communications|April 19, 2019
Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK-NF-κB signaling mediated inflammationJingjing Ben, Bin Jiang, Dongdong Wang, et al.
Molecular Oncology|January 28, 2014
DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivityMarijn T M van Jaarsveld, Maikel D Wouters, Antonius W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2013
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platformAnne-Joy M de Graan, Laure Elens, Marcel Smid, et al.
International Journal of Cancer|November 29, 2013
Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin usersLoes M Hollestein, Myrthe P P van Herk-Sukel, Rikje Ruiter, et al.
Frontiers in Neurology|May 10, 2017
The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after StrokeLena Ulm, Sarah Hoffmann, Darius Nabavi, et al.
British Journal of Cancer|August 24, 2013
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumoursC M M Gits, P F van Kuijk, M B E Jonkers, et al.
Pageof 13

Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
Cancer Biology & Therapy|November 19, 2005
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genesHerman Burger, Michael A den Bakker, Johan M Kros, et al.
Oncogene|October 10, 2012
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cellsM T M van Jaarsveld, J Helleman, A W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 2, 2012
A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patientsKarel Eechoute, Martin N Fransson, An K Reyners, et al.
Critical Care Medicine|March 4, 2017
Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) StudyPhilipp Schuetz, Robert Birkhahn, Robert Sherwin, et al.
Nature Communications|April 19, 2019
Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK-NF-κB signaling mediated inflammationJingjing Ben, Bin Jiang, Dongdong Wang, et al.
Molecular Oncology|January 28, 2014
DNA damage responsive microRNAs misexpressed in human cancer modulate therapy sensitivityMarijn T M van Jaarsveld, Maikel D Wouters, Antonius W M Boersma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2013
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platformAnne-Joy M de Graan, Laure Elens, Marcel Smid, et al.
International Journal of Cancer|November 29, 2013
Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin usersLoes M Hollestein, Myrthe P P van Herk-Sukel, Rikje Ruiter, et al.
Frontiers in Neurology|May 10, 2017
The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after StrokeLena Ulm, Sarah Hoffmann, Darius Nabavi, et al.
British Journal of Cancer|August 24, 2013
MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumoursC M M Gits, P F van Kuijk, M B E Jonkers, et al.
Pageof 13